April 15, 2020 07:20 AM EDT

Molecule-in-21-days AI startup Insilico adds Boehringer to list of Big Pharma partners

Jason Mast

Editor

Seven months after their headline-grabbing Nature Biotechnology study and in the throes of a Covid-19 research effort, Hong Kong-based AI startup Insilico Medicine has nabbed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Molecule-in-21-days AI startup Insilico adds Boehringer to list of Big Pharma partners

Jason Mast

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Mol­e­cule-in-21-days AI start­up In­sil­i­co adds Boehringer to list of Big Phar­ma part­ners

Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Molecule-in-21-days AI startup Insilico adds Boehringer to list of Big Pharma partners